Role of interferon alpha in allograft rejection.
Benizri
E J
EJ
Hôpital Pasteur, Service d'Urologie, Nice, France.
Gugenheim
J
J
Bernard
G
G
Tovey
M G
MG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology; D008252:Macaca fascicularis; D008297:Male; D016038:Skin Transplantation / Q000276:immunology* / Q000473:pathology; D014184:Transplantation, Homologous / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D016898:Interferon-alpha; D016572:Cyclosporine